Neurogene Eyes Phase 3 Registrational Study for Gene Therapy NGN-401 Following Positive Phase 1/2 Data

Published Date: 17 Nov 2024

NGN-401, an AAV9 gene therapy in development for Rett syndrome, was considered well-tolerated, with treated patients showing consistent gains in skill and developmental milestones.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

2.

Chemo causes lasting physical decline in breast cancer survivors

3.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets

4.

Race, Geography Linked to Gaps in Prostate Cancer Care

5.

DNA origami offers more accurate imaging in the fight against pancreatic cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot